Browse Category

Pharmacy

Roche ranked the most sustainable healthcare company in the DJSI

3 mins read

The FINANCIAL — For the eleventh time, Roche has been recognised as the most sustainable company in the Pharmaceuticals index of the Dow Jones Sustainability Indices (DJSI). This is based on an in-depth analysis of economic, social and environmental performance. The DJSI family of indices serves as a benchmark for investors who integrate sustainability considerations…

Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

4 mins read

The FINANCIAL — Gilead Sciences, Inc. and Novo Nordisk A/S announced results from a phase 2 proof-of-concept trial. The five-arm trial evaluated combinations of Novo Nordisk’s semaglutide, a GLP-1 receptor agonist, with Gilead’s investigational FXR agonist cilofexor and/or Gilead’s investigational ACC inhibitor firsocostat over 24 weeks in 108 people with non-alcoholic steatohepatitis (NASH). The results…

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

4 mins read

The FINANCIAL — Metagenomi, a next generation gene editing company launched by UC Berkeley scientists in 2018, successfully completed a USD 65 million Series A financing round and emerged from stealth mode today. The Series A round was led by Leaps by Bayer and Humboldt Fund. Other investors included Sozo Ventures, Agent Capital, InCube Ventures…

Pharmaceutical industries join to promise fair access to COVID-19 medicines and vaccines

3 mins read

The FINANCIAL — On the occasion of the World Health Assembly, the world’s research-based and generic & biosimilar pharmaceutical industry bodies delivered a statement declaring their shared commitment to equitable access to COVID-19 medicines and vaccines. In their joint statement, the two global pharmaceutical industry bodies acknowledge their responsibility and commitment to support the international response to the…

Bayer submits marketing authorization applications for finerenone in the U.S. and the EU

2 mins read

The FINANCIAL — Bayer announced the submission of regulatory applications to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) seeking approval of finerenone for patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Finerenone is a first-in-class investigational non-steroidal, selective mineralocorticoid receptor antagonist (MRA) that demonstrated renal and…

AstraZeneca’s Calquence approved in the EU for the treatment of most common type of leukaemia in adults

9 mins read

The FINANCIAL —  AstraZeneca’s Calquence (acalabrutinib), a next-generation selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in the European Union (EU) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults. The approval by the European Commission was based on positive results from two Phase III…

FDA approved AstraZeneca’s Brilinta to reduce the risk of stroke

3 mins read

The FINANCIAL — AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with acute ischemic stroke (National Institutes of Health Stroke Scale score ≤5) or high-risk transient ischaemic attack (TIA). The approval by the US Food and Drug Administration (FDA) was based…

Astellas announced that China NMPA approved XTANDI for the treatment of prostate cancer

5 mins read

The FINANCIAL — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the China National Medical Products Administration (NMPA) has approved XTANDI® (enzalutamide soft capsules) for the treatment of adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) with high risk of metastasis. This is the second approved indication in China for enzalutamide, which is…

Roche to present new data across 16 blood disorders at the ASH 2020 Annual Meeting

7 mins read

The FINANCIAL — Roche  today announced that new data for its approved and investigational medicines will be presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition from 5 – 8 December 2020. Eleven Roche medicines will be featured in more than 80 abstracts, including 22 oral presentations. With studies spanning…

EU approved AstraZeneca’s Forxiga for heart failure

4 mins read

The FINANCIAL — AstraZeneca’s Forxiga (dapagliflozin) has been approved in the European Union (EU) for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF) in adults with and without type-2 diabetes (T2D). Heart failure (HF) is a life-threatening chronic disease that prevents the heart from pumping sufficient levels of blood around the body. It…

Bayer reported sales decrease by 5.1%

15 mins read

The FINANCIAL — Bayer reported third quarter financial results. Highlights Group sales decrease by 5.1 percent (Fx & portfolio adj.) to 8.506 billion euros / EBITDA before special items falls 21.4 percent to 1.795 billion euros / Substantial decline in sales and earnings at Crop Science, heavily impacted by seasonal and currency effects / Pharmaceuticals…

EU Commission approved Roche’s Tecentriq in combination with Avastin for the treatment of people with liver cancer

4 mins read

The FINANCIAL — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. “Tecentriq in combination with Avastin is the first treatment to be…

AstraZeneca to sell commercial rights to Atacand in more than 70 countries to Cheplapharm

2 mins read

The FINANCIAL — AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in around 70 countries globally to Cheplapharm Arzneimittel GmbH (Cheplapharm). Atacand is a prescription medicine approved for the treatment of heart failure (HF) and hypertension. Atacand Plus is approved for the treatment of hypertension. Ruud Dobber, Executive…

Novo Nordisk’s operating profit increased by 6% in Danish kroner and by 7% at constant exchange rates

2 mins read

The FINANCIAL – Novo Nordisk published financial report for the period 1 January 2020 to 30 September 2020 Sales increased by 6% in Danish kroner and by 7% at CER to DKK 94.8 billion. Sales in International Operations increased by 9% in Danish kroner (12% at CER), and sales in North America Operations increased by…

Bayer launches first Global Creative Council

5 mins read

The FINANCIAL — Bayer launches its first Global Creative Council. This global initiative brings together senior leaders from a variety of companies representing strategic agencies as well as industry brands. The Council aims to harness progressive and collective creativity of industry marketing experts to deliver the Bayer Consumer Health Division’s purpose of empowering the transformation…

1 2 3 130